US Biotech Stocks Regain Momentum... IPO Fundraising Jumps 65%

11 IPOs... $1.7 Billion Raised

This year, the amount of funds raised through initial public offerings (IPOs) by U.S. biotechnology companies has increased by more than 60% compared to last year. This reflects the emerging expectations of a pivot by the Federal Reserve (Fed), which has maintained high interest rates for an extended period. However, as the timing of interest rate cuts has been pushed back to the second half of the year due to a resilient economy, some analysts suggest that fundraising has not been as substantial as initially anticipated by the market.

Financial information firm Dealogic reported on the 10th that the amount of funds raised through the IPO market by U.S. biotechnology companies currently stands at approximately $1.7 billion this year. This represents a roughly 64% surge compared to the same period last year. The amount raised by previously listed companies recorded a 100% increase year-over-year, reaching $16.5 billion.

According to the U.S. biotechnology industry, 11 companies have gone public on U.S. stock exchanges through IPOs this year. Additionally, dozens of companies have reportedly submitted securities registration statements to the U.S. Securities and Exchange Commission (SEC) for IPOs. Startups Alumis and Upstream are representative examples. Alumis is developing a targeted treatment for severe psoriasis, a skin disease, while Upstream is developing a candidate drug for severe asthma treatment; both are likely to be listed on Nasdaq.

Biotechnology companies have struggled due to difficulties in fundraising amid the high interest rates sustained since the COVID-19 pandemic, leading to interruptions in various research and development (R&D) activities. However, with expectations emerging that the benchmark interest rate will be cut within the year, investment sentiment in the industry is reportedly improving.

Nonetheless, experts believe that the biotechnology sector's conditions can only substantially improve once remaining uncertainties?such as the U.S. presidential election and the actual implementation of interest rate cuts?are resolved. The market evaluates that the reason most companies listed this year are trading at prices lower than their IPO offering prices is due to these factors.

Mike Perron, a biotechnology analyst at RW Baird, said, “Trader sentiment cooled in the second quarter of this year as expectations for how quickly the Fed would cut rates were postponed.” He added, “Some biotechnology companies, for which funding is relatively less urgent, may delay their listings until after the election and the actual timing of interest rate cuts.”

This content was produced with the assistance of AI translation services.